
-
Merck & Co NYSE:MRK Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Location: 126 East Lincoln Avenue, Rahway, NJ, 07065, United States | Website: https://www.merck.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
217.5B
Cash
9.228B
Avg Qtr Burn
N/A
Short % of Float
1.65%
Insider Ownership
0.06%
Institutional Own.
80.68%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PADCEV® (enfortumab vedotin-ejfv) + KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, Urothelial cancer | Approved Update | |
KEYTRUDA+ chemotherapy Details Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma | Approved Update | |
GARDASIL 9 Details Human Papillomavirus 9-valent Vaccine, Human papillomavirus | Approved Update | |
M-M-R®II, VARIVAX®, and ProQuad® Details Vaccine, Viral infection | Approved Update | |
KEYTRUDA Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Update | |
KEYTRUDA in comb w/chemotherapy Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
KEYTRUDA+ chemotherapy Details Cancer, Biliary Tract Cancer | Approved Quarterly sales | |
KEYTRUDA +carboplatin + paclitaxel Details Cancer, Solid tumor/s, Carcinoma , Endometrial cancer | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
KEYTRUDA+ Padcev (enfortumab vedotin) Details Cancer, Urothelial carcinoma | Approved Quarterly sales | |
KEYTRUDA+ trastuzumab+ chemotherapy Details Gastric cancer, Cancer, Gastroesophageal adenocarcinomas | Approved Quarterly sales | |
ERVEBO Details Ebola | Approved Quarterly sales | |
WELIREG® (belzutifan) Details Pheochromocytoma , Paraganglioma | Approved Quarterly sales | |
CAPVAXIVE (V116) Details Pneumococcal Conjugate Vaccine | Approved Quarterly sales | |
KEYTRUDA + chemotherapy Details Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | Approved Quarterly sales | |
LYNPARZA(olaparib) + abi/pred Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
WELIREG® (belzutifan) Details Renal cell carcinoma, von Hippel-Lindau, Cancer, Hemangioblastoma, Pancreatic neuroendocrine tumors | Approved Quarterly sales | |
WINREVAIR (sotatercept-csrk) Details Pulmonary arterial hypertension | Approved Quarterly sales | |
KEYTRUDA in comb w/ EBRT + brachytherapy Details Cervical cancer, Cancer | Approved Quarterly sales | |
PREVYMIS™ (letermovir) Details Cytomegalovirus, Viral infection | Approved Quarterly sales | |
KEYTRUDA (pembrolizumab) injection Details Gastric cancer, Gastroesophageal adenocarcinomas | PDUFA Approval decision | |
KEYTRUDA + Berahyaluronidase Alfa Details Non-small cell lung carcinoma | PDUFA Approval decision | |
KEYTRUDA® (pembrolizumab) Details Head and neck squamous cell carcinoma, Cancer | PDUFA Approval decision | |
Clesrovimab (MK-1654) Details Respiratory syncytial virus | PDUFA Approval decision | |
Islatravir+ Doravirine Details Viral infection, Human immunodeficiency virus | BLA Submission | |
Gefapixant (MK-7264) Details Chronic cough | NDA FDA meeting | |
MK-1084 +/- KEYTRUDA® Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
LAGEVRIO™ (molnupiravir) Details Viral infection, COVID-19 | Phase 3 Data readout | |
Ifinatamab Deruxtecan (I-DXd) Details Small cell lung cancer, Cancer | Phase 3 Data readout | |
Tulisokibart (PRA023) (Anti-TL1A mAb) Details Crohns disease | Phase 3 Data readout | |
KEYTRUDA+pemetrexed Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Ifinatamab Deruxtecan (I-DXd) Details Esophageal Squamous Cell Carcinoma | Phase 3 Data readout | |
MK-0616 Details Cardiovascular disease , Hypercholesterolemia | Phase 3 Data readout | |
MK-2870 Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Nemtabrutinib Details Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia | Phase 3 Data readout | |
MK-5684 (ODM-208) Details Cancer, Castration-resistant prostate cancer | Phase 3 Data readout | |
Bomedemstat Details Thrombocythemia | Phase 3 Data readout | |
Tulisokibart (MK-7240) (PRA023) (Anti-TL1A mAb) Details Irritable bowel syndrome, Crohns disease, Ulcerative colitis | Phase 3 Data readout | |
Bomedemstat Details Thrombocytopenia | Phase 3 Data readout | |
Patritumab deruxtecan (HER3-DXd) Details Non-small cell lung carcinoma | Phase 3 Data readout | |
Clesrovimab (MK-1654) Details Respiratory syncytial virus | Phase 3 Data readout | |
KEYTRUDA® plus paclitaxel +/- bevacizumab Details Platinum-Resistant Recurrent Ovarian Cancer | Phase 3 Update | |
KEYTRUDA + favezelimab Details Cancer, Metastatic colorectal cancer | Phase 3 Update | |
KEYTRUDA Details Cancer, Solid tumor/s, Urothelial carcinoma | Phase 3 Update | |
Zilovertamab (MK-2140) Details Previously Untreated Diffuse large B cell lymphoma | Phase 3 Update | |
Phase 3 Update | ||
KEYTRUDA® (pembrolizumab)+ LYNPARZA® (olaparib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
KEYTRUDA + LENVIMA Details Cancer, Renal cell carcinoma | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Carcinoma , Endometrial cancer | Phase 3 Update | |
KEYTRUDA Details Cancer, Renal cell carcinoma | Phase 3 Update | |
KEYTRUDA Details Solid tumor/s, Cancer, Triple-negative breast cancer , Breast cancer | Phase 3 Update | |
KEYTRUDA + LENVIMA in comb w/TACE Details Cancer, Hepatocellular carcinoma | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
MK-1084 + cetuximab + mFOLFOX6 Details unresectable or metastatic CRC | Phase 3 Update | |
KEYTRUDA Details Cancer, Solid tumor/s, ER+/HER2- breast cancer | Phase 3 Update | |
MK-0616 Details Hypercholesterolemia | Phase 3 Initiation | |
Restoret (MK-3000, formerly EYE103) Details Eye disease , Diabetic macular edema | Phase 2/3 Data readout | |
Raludotatug Deruxtecan Details Platinum-resistant ovarian cancer, Cancer | Phase 2/3 Data readout | |
Zilovertamab (MK-2140) Details r/r Diffuse large B cell lymphoma | Phase 2/3 Update | |
Efinopegdutide (MK-6024) Details Non-Alcoholic Fatty Liver Disease, Liver disease | Phase 2b Initiation | |
Bomedemstat Details Myelofibrosis | Phase 2 Data readout | |
Patritumab deruxtecan (HER3-DXd) Details Breast cancer, Cancer | Phase 2 Data readout | |
Ifinatamab Deruxtecan (I-DXd) Details Small cell lung cancer, Cancer | Phase 2 Update | |
PRA023 (Anti-TL1A mAb) Details Systemic sclerosis, Autoimmune disease | Phase 2 Update | |
PRA023 (Anti-TL1A mAb) Details Autoimmune disease, Systemic sclerosis | Phase 2 Update | |
Belzutifan + cabozantinib Details Cancer, Renal cell carcinoma | Phase 2 Update | |
HPN328 (DLL3) +/- atezolizumab Details Cancer, Small cell lung cancer, Solid tumor/s | Phase 1/2 Update | |
HPN217 (BCMA) Details Multiple myeloma | Phase 1 Update | |
PRA052 Details Inflammatory bowel disease | Phase 1 Update | |
MK-1084 Details Colorectal cancer, Non-small cell lung carcinoma | Phase 1 Update | |
KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Failed Discontinued | |
KEYTRUDA + LENVIMA Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued |